소화기계 감염 진료지침 권고안

키워드

참고문헌 (324)

1. World Health Organization, "World health report 2003: shaping the future" (2003), WHO
2. Korea Centers for Disease Control and Prevention, "Water & foodborne diseases outbreaks in Korea, 2008", Public Health Weekly Report, 2, pp.584~590 (2009)
3. Seung-Hak Cho, "Enteric Bacteria Isolated from Acute Diarrheal Patients in the Republic of Korea between the Year 2004 and 2006", The Journal of Microbiology, 46(3), pp.325~330 (2008), 한국미생물학회
4. Jae In Lee, "Surveillance of Acute Gastroenteritis in Seoul, Korea, During May 2004 and June 2007", Journal of Bacteriology and Virology, 39(4), pp.363~371 (2009), 대한미생물학회
5. Korea Centers for Disease Control and Prevention, "The analysis on the prevalence status and characteristics of bacterial pathogens causing acute diarrhea in Korea, 2007", Public Health Weekly Report, 1, pp.116~122 (2008)
6. Lim HS, "Contributing factors of infectious waterborne and foodborne outbreaks in Korea", Journal of the Korean Medical Association, 50, pp.582~591 (2007)
7. Joo HJ, "An outbreak of Yersinia pseudotuberculosis infection", J Korean Pediatr Soc, 33, pp.342~350 (1990)
8. Shin HR, "An epidemiologic investigation of typhoid fever outbreak in Pusan, 1996", Korean J Epidemiol, 19, pp.122~130 (1997)
9. Lim HS, "Epidemiologic investigation of an outbreak of shigellosis in Kyongju, Korea", Korean J Prev Med, 33, pp.1~9 (2000)
10. 박성훈, "Enterotoxigenic Escherichia coli Outbreak in a High School", Infection and Chemotherapy, 38(1), pp.30~38 (2006), 대한감염학회
11. 민영선, "성주군 S 초등학교 및 중학교에서 집단 발생한 세균성 이질에 관한 역학조사", 예방의학회지, 38(2), pp.189~196 (2005), 대한예방의학회
12. 임현술, "2004년 영천시 D 초등학교에서 집단 발생한 살모넬라증", 예방의학회지, 38(4), pp.457~464 (2005), 대한예방의학회
13. Kim KY, "Pulsed-Field Gel Electrophoresis analysis of a Salmonella london outbreak in neontes", J Korean Soc Neonatol, 8, pp.222~228 (2001)
14. 김준영, "국내에서 최초로 분리된 Shigella dysenteriae type 8에 의한 세균성 이질 환자 집단 발생", 대한임상미생물학회지, 8(2), pp.153~159 (2005), 대한임상미생물학회
15. Jin SM, "An epidemiological survey on the outbreak of cholera of overseas travelers in Daejeon", Korean Journal of Epidemiology, 28, pp.119~128 (2006)
16. Giannella RA, "Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro", Gut, 13, pp.251~256 (1972)
17. Rabbani GH, "Short-chain fatty acids improve clinical, pathologic, and microbiologic features of experimental shigellosis", J Infect Dis, 179, pp.390~397 (1999)
18. Donnelly MA, "Two nonadjacent regions in enteroaggregative Escherichia coli flagellin are required for activation of toll-like receptor 5", J Biol Chem, 277, pp.40456~40461 (2002)
19. Lehrer RI, "Defensins: antimicrobial and cytotoxic peptides of mammalian cells", Annu Rev Immunol, 11, pp.105~128 (1993)
20. Jiang ZD, "Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region", J Infect Dis, 188, pp.506~511 (2003)
21. Jiang ZD, "A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea", Am J Gastroenterol, 101, pp.1112~1116 (2006)
22. Mohamed JA, "A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico", Clin Infect Dis, 44, pp.945~952 (2007)
23. Lindesmith L, "Human susceptibility and resistance to Norwalk virus infection", Nat Med, 9, pp.548~555 (2003)
24. Farthing M, "World Gastroenterology Organisation practice guideline: Acute diarrhea", ~ (2008)
25. Guerrant RL, "Practice guidelines for the management of infectious diarrhea", Clin Infect Dis, 32, pp.331~351 (2001)
26. Thielman NM, "Clinical practice. Acute infectious diarrhea", N Engl J Med, 350, pp.38~47 (2004)
27. DuPont HL, "Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology", Am J Gastroenterol, 92, pp.1962~1975 (1997)
28. Navaneethan U, "Mechanisms of infectious diarrhea", Nat Clin Pract Gastroenterol Hepatol, 5, pp.637~647 (2008)
29. Wolf MK, "Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic Escherichia coli", Clin Microbiol Rev, 10, pp.569~584 (1997)
30. Centers for Disease Control and Prevention, "Foodborne outbreaks of enterotoxigenic Escherichia coli -Rhode Island and New Hampshire, 1993", MMWR Morb Mortal Wkly Rep, 43, pp.81~89 (1994)
31. Sanchez J, "Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea", Curr Opin Immunol, 17, pp.388~398 (2005)
32. Shogomori H, "Cholera toxin is found in detergent-insoluble rafts", domains at the cell surface of hippocampal neurons but is internalized via a raft-independent mechanism, 2001, pp.276, 9182~9188
33. Mourad FH, "Role of 5-hydroxytryptamine type 3 receptors in rat intestinal fluid and electrolyte secretion induced by cholera and Escherichia coli enterotoxins", Gut, 37, pp.340~345 (1995)
34. Canani RB, "Inhibitory effect of HIV-1 Tat protein on the sodium-D-glucose symporter of human intestinal epithelial cells", AIDS, 20, pp.5~10 (2006)
35. Griffin PM, "Escherichia coli O157:H7 and other enterohemorrhagic E. coli in Infections of the Gastrointestinal tract", pp.627~642 (2002), Lippincott Williams & Wilkins
36. Su C, "Escherichia coli O157:H7 infection in humans", Ann Intern Med, 123, pp.698~714 (1995)
37. Phalipon A, "Shigellosis: innate mechanisms of inflammatory destruction of the intestinal epithelium, adaptive immune response, and vaccine development", Crit Rev Immunol, 23, pp.371~401 (2003)
38. Giannella RA, "Sleisenger & Fordtran's gastrointestinal and liver disease", pp.2333~2391 (2006), Elsevier Saunders
39. Grassl GA, "Pathogenesis of enteric Salmonella infections", Curr Opin Gastroenterol, 24, pp.22~26 (2008)
40. Hickey TE, "Campylobacter jejuni cytolethal distending toxin mediates release of interleukin-8 from intestinal epithelial cells", Infect Immun, 68, pp.6535~6541 (2000)
41. DuPont HL, "Clinical practice: bacterial diarrhea", N Engl J Med, 361, pp.1560~1569 (2009)
42. Talan D, "Etiology of bloody diarrhea among patients presenting to United States emergency departments: prevalence of Escherichia coli O157:H7 and other enteropathogens", Clin Infect Dis, 32, pp.573~580 (2001)
43. Shah N, "Global etiology of travelers' diarrhea: systematic review from 1973 to the present", Am J Trop Med Hyg, 80, pp.609~614 (2009)
44. DuPont HL, "Expert review of the evidence base for self-therapy of travelers' diarrhea", J Travel Med, 16, pp.161~171 (2009)
45. DuPont HL, "A randomized, doubleblind, placebo controlled trial of rifaximin to prevent travelers' diarrhea", Ann Intern Med, 142, pp.805~812 (2005)
46. DuPont HL, "Expert review of the evidence base for prevention of travelers' diarrhea", J Travel Med, 16, pp.149~160 (2009)
47. Kelly CP, "Clostridium difficile -more difficult than ever", N Engl J Med, 359, pp.1932~1940 (2008)
48. Munoz C, "Characteristics of Shigella sonnei infection of volunteers: signs, symptoms, immune responses, changes in selected cytokines and acutephase substances", Am J Trop Med Hyg, 53, pp.47~54 (1995)
49. Marks MI, "Yersinia enterocolitic a gastroenteritis: a prospective study of clinical bacteriologic and epidemiologic features", J Pediatr, 96, pp.26~31 (1980)
50. Mikhail IA, "Microbiologic and clinical study of acute diarrhea in children in Aswan, Egypt", Scand J Infect Dis, 21, pp.59~65 (1989)
51. Speelman P, "Differential clinical features and stool findings in shigellosis and amoebic dysentery", Trans Roy Soc Trop Med Hyg, 81, pp.549~551 (1987)
52. Skirrow MB, "Campylobacter jejuni in Infections of the gastrointestinal tract", pp.825~848 (1995), Raven Press
53. Rodrigue DC, "A university outbreak of Escherichia coli O157:H7 infections associated with roast beef and an unusually benign clinical course", J Infect Dis, 172, pp.1122~1125 (1995)
54. Stermer E, "Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study", Clin Infect Dis, 43, pp.898~901 (2006)
55. Tam CC, "Incidence of Guillain-Barre syndrome among patients with Campylobacter infection: a general practice research database study", J Infect Dis, 194, pp.95~97 (2006)
56. Townes JM, "Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a populationbased study", Ann Rheum Dis, 67, pp.1689~1696 (2008)
57. Harris JC, "Fecal leukocytes in diarrheal illness", Ann Intern Med, 76, pp.697~703 (1972)
58. Guerrant RL, "Schwartzman JD. A cost effective and effective approach to the diagnosis and management of acute infectious diarrhea", Bull N Y Acad Med, 63, pp.484~499 (1987)
59. Ethelberg S, "The significance of the number of submitted samples and patient-related factors for faecal bacterial diagnostics", Clin Microbiol Infect, 13, pp.1095~1099 (2007)
60. Nalin DR, "Oral maintenance therapy for cholera in adults", Lancet, 2, pp.370~373 (1968)
61. Duggan C, "The management of acute diarrhea in children: oral rehydration, maintenance, and nutritional therapy. Centers for Disease Control and Prevention", MMWR Recomm Rep, 41, pp.1~20 (1992)
62. Hahn S, "Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: systematic review", BMJ, 323, pp.81~85 (2001)
63. "New formula for oral rehydration salts will save millions of lives"[URL]
64. Lee JS, "Management of acute infectious diarrhea", Journal of the Korean Medical Association, 50, pp.600~605 (2007)
65. Pai H, "Acute infectious diarrhea", Korean Journal of Medicine, 73, pp.114~118 (2007)
66. Brown KH, "Effect of continued oral feeding on clinical and nutritional outcomes of acute diarrhea in children", J Pediatr, 112, pp.191~200 (1988)
67. Molla AM, "Food-based oral rehydration salt solution for acute childhood diarrhoea", Lancet, 2, pp.429~431 (1989)
68. Duggan C, ""Feeding the gut": the scientific basis for continued enteral nutrition during acute diarrhea", J Pediatr, 131, pp.801~808 (1997)
69. Sandhu BK, "Rationale for early feeding in childhood gastroenteritis", J Pediatr Gastroenterol Nutr, 33(Suppl 2), pp.S13~S16 (2001)
70. Adachi JA, "Empirical antimicrobial therapy for traveler's diarrhea", Clin Infect Dis, 31, pp.1079~1083 (2000)
71. Zhang X, "Quinolone antibiotics induce Shiga toxinencoding bacteriophages, toxin production, and death in mice", J Infect Dis, 181, pp.664~670 (2000)
72. Ohara T, "Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response", Antimicrob Agents Chemother, 46, pp.3478~3483 (2002)
73. Ochoa TJ, "Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli", Antimicrob Agents Chemother, 51, pp.2837~2841 (2007)
74. Tribble DR, "Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen", Clin Infect Dis, 44, pp.338~346 (2007)
75. 박은희, "설사환자에서 Campylobacter jejuni의 분리 및 항생제 감수성 특성", 생명과학회지, 17(6), pp.811~815 (2007), 한국생명과학회
76. Shin-Moo Kim, "Cytolethal Distending Toxin Production, Genotypes and Atimicrobial Susceptibility of Campylobacter jejuni Isolates from Diarrhea Patients and Chickens", Journal of Bacteriology and Virology, 38(4), pp.207~219 (2008), 대한미생물학회
77. 질병관리본부, "ESBL생성 이질균 감염증 집단 발생의 적정관리 방안", ~ (2007)
78. National Institute of Health, "Extended-spectrum β-lactamase 를 생산하는 Shigella sonnei 유행", 감염병발생정보, 16, pp.1~5 (2005)
79. National Institute of Health, "국가적 항균제 내성 감시 현황", 감염병발생정보, 14, pp.273~283 (2003)
80. Das S, "Trend of antibiotic resistance of Vibrio cholerae strains from East Delhi", Indian J Med Res, 127, pp.478~482 (2008)
81. 김용희, "지역사회 및 병원 임상검체에서 분리한 대장균의 항생제 내성 양상", 미생물학회지, 42(4), pp.252~256 (2006), 한국미생물학회
82. Spruill WJ, "Diarrhea, constipation, and irritable bowel syndrome in Pharmacotherapy a pathophysiologic approach", pp.617~623 (2007), McGraw Hill Medical
83. Wang HH, "A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults", World J Gastroenterol, 11, pp.1540~1543 (2005)
84. Szajewska H, "Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children", Aliment Pharmacol Ther, 25, pp.257~264 (2007)
85. Van Niel CW, "Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis", Pediatrics, 109, pp.678~684 (2002)
86. Floch MH, "Recommendations for probiotic use--2008", J Clin Gastroenterol, 42(Suppl 2), pp.S104~S108 (2008)
87. McFarland LV, "Prevention of beta-lactamassociated diarrhea by Saccharomyces boulardii compared with placebo", Am J Gastroenterol, 90, pp.439~448 (1995)
88. Bartlett JG, "Antibiotic-associated diarrhea", Clin Infect Dis, 15, pp.573~581 (1992)
89. Bartlett JG, "Clinical practice. Antibiotic-associated diarrhea", N Engl J Med, 346, pp.334~339 (2002)
90. Hyun Joo Song, "Antibiotic-Associated Diarrhea: Candidate Organisms other than Clostridium Difficile", The Korean Journal of Internal Medicine, 23(1), pp.9~15 (2008), 대한내과학회
91. Bartlett JG, "Clostridium difficile : clinical considerations", Rev Infect Dis, 12(Suppl 2), pp.S243~S251 (1990)
92. Kelly CP, "Clostridium difficile colitis", N Engl J Med, 330, pp.257~262 (1994)
93. Hookman P, "Clostridium difficile associated infection, diarrhea and colitis", World J Gastroenterol, 15, pp.1554~1580 (2009)
94. 태정현, "The First Case of Antibiotic-associated Colitis by Clostridium difficile PCR Ribotype 027 in Korea", Journal of Korean Medical Science, 24(3), pp.520~524 (2009), 대한의학회
95. 변태준, "Clostridium difficile-Associated Disease (CDAD)의 최근 임상양상의 변화", 대한소화기학회지, 54(1), pp.13~19 (2009), 대한소화기학회
96. Fekety R, "Guidelines for the diagnosis and management of Clostridium difficile -associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee", Am J Gastroenterol, 92, pp.739~750 (1997)
97. Cohen SH, "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)", Infect Control Hosp Epidemiol, 31, pp.431~455 (2010)
98. Olson MM, "Ten years of prospective Clostridium difficile -associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991", Infect Control Hosp Epidemiol, 15, pp.371~381 (1994)
99. Johnson S, "Nosocomial Clostridium difficile colonisation and diseases", Lancet, 336, pp.97~100 (1990)
100. Samore MH, "Clostridium difficile colonization and diarrhea at a tertiary care hospital", Clin Infect Dis, 18, pp.181~187 (1994)
101. Pepin J, "Management and outcomes of a first recurrence of Clostridium difficile -associated disease in Quebec, Canada", Clin Infect Dis, 42, pp.758~764 (2006)
102. Lee KS, "Who are susceptible to pseudomembranous colitis among patients with presumed antibiotic-associated diarrhea?", Dis Colon Rectum, 49, pp.1552~1558 (2006)
103. Gerding DN, "Diagnosis of Clostridium difficile -associated disease: patient selection and test perfection", Am J Med, 100, pp.485~486 (1996)
104. Aichinger E, "Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay", J Clin Microbiol, 46, pp.3795~3797 (2008)
105. Lyras D, "Toxin B is essential for virulence of Clostridium difficile", Nature, 458, pp.1176~1179 (2009)
106. Shin BM, "Emerging toxin A-B+ variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea", Diagnostic Microbiology and Infectious Disease, 60, pp.333~337 (2008)
107. Shin BM, "Multicentre study of the prevalence of toxigenic Clostridium difficile in Korea: results of a retrospective study 2000-2005", Journal of Medical Microbiology, 57, pp.697~701 (2008)
108. Bouza E, "Clinical manifestations, treatment and control of infections caused by Clostridium difficile", Clin Microbiol Infect, 11(Suppl 4), pp.57~64 (2005)
109. Reller ME, "Yield of stool culture with isolate toxin testing versus a twostep algorithm including stool toxin testing for detection of toxigenic Clostridium difficile", J Clin Microbiol, 45, pp.3601~3605 (2007)
110. Shin BM, "Algorithm combining toxin immunoassay and stool culture for diagnosis of Clostridium difficile infection", J Clin Microbiol, 47, pp.2952~2956 (2009)
111. 김새희, "Clostridium difficile 관련 설사의 진단에서 S상결장경 검사의 유용성", 대한내과학회지, 78(3), pp.318~324 (2010), 대한내과학회
112. Modena S, "Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile -associated diarrhea", J Clin Gastroenterol, 40, pp.49~54 (2006)
113. Nelson R, "Antibiotic treatment for Clostridium difficile -associated diarrhea in adults. Cochrane Database Syst Rev 2007;CD004610", ~ (2007)
114. 박혜선, "항생제 연관 설사의 치료", 대한소화기학회지, 54(1), pp.5~12 (2009), 대한소화기학회
115. Loo VG, "A predominantly clonal multiinstitutional outbreak of Clostridium difficile -associated diarrhea with high morbidity and mortality", N Engl J Med, 353, pp.2442~2449 (2005)
116. Pepin J, "Clostridium difficile -associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity", CMAJ, 171, pp.466~472 (2004)
117. Miller M, "Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality", Clin Infect Dis, 50, pp.194~201 (2010)
118. Teasley DG, "Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile - associated diarrhoea and colitis", Lancet, 2, pp.1043~1046 (1983)
119. Wenisch C, "Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile - associated diarrhea", Clin Infect Dis, 22, pp.813~818 (1996)
120. "Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practice Advisory Committee (HICPAC)", MMWR Recomm Rep, 44, pp.1~13 (1995)
121. Musher DM, "Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole", Clin Infect Dis, 40, pp.1586~1590 (2005)
122. Pepin J, "Increasing risk of relapse after treatment Clostridium difficile colitis in Quebec, Canada", Clin Infect Dis, 40, pp.1591~1597 (2005)
123. Aslam S, "Treatment of Clostridium difficile associated disease: old therapies and new strategies", Lancet Infect Dis, 5, pp.549~557 (2005)
124. Wilcox MH, "Diarrhea caused by Clostridium difficile : response time for treatment with metronidazole and vancomycin", J Antimicrob Chemother, 36, pp.673~679 (1995)
125. Zar FA, "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile -associated diarrhea, stratified by disease severity", Clin Infect Dis, 45, pp.302~307 (2007)
126. Apisarnthanarak A, "Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature", Clin Infect Dis, 35, pp.690~696 (2002)
127. Lamontagne F, "Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain", Ann Surg, 245, pp.267~272 (2007)
128. Longo WE, "Outcome after colectomy for Clostridium difficile colitis", Dis Colon Rectum, 47, pp.1620~1626 (2004)
129. Nair S, "Clostridium difficile colitis: factors influencing treatment failure and relapse-a prospective evaluation", Am J Gastroenterol, 93, pp.1873~1876 (1998)
130. Kyne L, "Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea", Lancet, 357, pp.189~193 (2001)
131. Kapoor K, "Evaluation of metronidazole toxicity: a prospective study", Int J Clin Pharmacol Res, 19, pp.83~88 (1999)
132. McFarland LV, "Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease", Am J Gastroenterol, 97, pp.1769~1775 (2002)
133. McPherson S, "Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea", Dis Colon Rectum, 49, pp.640~645 (2006)
134. Tielman NM, "Enteric fever and other causes of abdominal symptoms with fever in Mandell, Douglas, and Bennett's Principles and practice of infectious diseases", pp.1399~1405 (2010), Churchill Livingstone Elsevier
135. Pai H, "Salmonella and Shigella infections in Infectious Diseases", pp.423~433 (2007), Koonja
136. Yoo Sunmi, "Epidemiology of Salmonella enterica Serotype Typhi Infections in Korea for Recent 9 Years: Trends of Antimicrobial Resistance", Journal of Korean Medical Science, 19(1), pp.15~20 (2004), 대한의학회
137. Lee K, "Emergence of multidrug-resistant Salmonella enterica serovar Typhi in Korea", Antimicrob Agents Chemother, 48, pp.4130~4135 (2004)
138. 임현술, "우리나라 전염성 질환의 변화 양상", 예방의학회지, 38(2), pp.117~124 (2005), 대한예방의학회
139. "Database Web Statistics System"[URL]
140. Seo S, "The serogroup and antimicrobial resistance of Salmonella spp. isolated from the clinical specimens during 6 years in a tertiary university hospital", Korean Journal of Clinical Microbiology, 7, pp.72~76 (2004)
141. 박재은, "Ciprofloxacin 치료에 반응이 없는 유입된 장티푸스 1예", Infection and Chemotherapy, 49(1), pp.46~49 (2007), 대한감염학회
142. 김대범, "시프로프록사신에 반응하지 않은 해외유입 장티푸스 3예", 대한내과학회지, 77(3), pp.377~381 (2009), 대한내과학회
143. 이광선, "Ciprofloxacin 치료에 실패한 국내에서감염된 장티푸스 1예", Infection and Chemotherapy, 40(3), pp.175~178 (2008), 대한감염학회
144. Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. M100-S20. Wayne, PA: CLSI", ~ (2010)
145. Bhan MK, "Typhoid and paratyphoid fever", Lancet, 366, pp.749~762 (2005)
146. Rahman M, "Emergence of multidrugresistant Salmonella enterica serotype Typhi with decreased ciprofloxacin susceptibility in Bangladesh", Epidemiol Infect, 134, pp.433~438 (2006)
147. Ray P, "Predictive efficacy of nalidixic acid resistance as a marker of fluoroquinolone resistance in Salmonella enterica var Typhi", Indian J Med Res, 124, pp.105~108 (2006)
148. Crump JA, "Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae", Clin Infect Dis, 37, pp.75~81 (2003)
149. Parry CM, "Typhoid fever", N Engl J Med, 347, pp.1770~1782 (2002)
150. Shukla S, "100 years of Widal test and its reappraisal in an endemic area", Indian J Med Res, 105, pp.53~57 (1997)
151. Lee CK, "Usefulness of Widal test in the diagnosis of typhoid fever", Korean J Infect Dis, 33, pp.206~209 (2001)
152. Gotuzzo E, "Quinolones in typhoid fever", Infect Dis Clin Pract, 3, pp.345~351 (1994)
153. White NJ, "The treatment of typhoid fever", Curr Opin Infect Dis, 9, pp.298~302 (1996)
154. Rupali P, "Treatment failure in typhoid fever with ciprofloxacin susceptibile Salmonella enterica serotype Typhi", Diagn Microbiol Infect Dis, 49, pp.1~3 (2004)
155. Crump JA, "Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study", Antimicrob Agents Chemother, 52, pp.1278~1284 (2008)
156. Threlfall EJ, "Ciprofloxacin-resistant Salmonella typhi and treatment failure", Lancet, 353, pp.1590~1591 (1999)
157. Chinh NT, "A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever", Antimicrob Agents Chemother, 44, pp.1855~1859 (2000)
158. Effa EE, "Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2008;CD006083", ~ (2008)
159. Parry CM, "Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever", Antimicrob Agents Chemother, 51, pp.819~825 (2007)
160. Thaver D, "A comparison of fluoroquinolones versus other antibiotics for treating enteric fever: meta-analysis", BMJ, 338, pp.b1865~ (2009)
161. Thaver D, "Fluoroquinolone for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2008;CD004530", ~ (2008)
162. Bhutta ZA, "Quinolone-resistant Salmonella paratyphi B meningitis in a newborn: a case report", J Infect, 35, pp.308~310 (1997)
163. Girgis NI, "Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhisepticemia in children", Pediatri Infect Dis J, 14, pp.603~605 (1995)
164. Mandal S, "In vitro efficacy of ciprofloxacin alone and in combination with amoxicillin against Salmonella typhi isolates", Indian J Exp Biol, 41, pp.360~362 (2003)
165. Mandal S, "Combination effect of ciprofloxacin and gentamicin against clinical isolates of Salmonella enterica serovar Typhi with reduced susceptibility to ciprofloxacin", Jpn J Infect Dis, 56, pp.156~157 (2003)
166. 김동민, "Nalidixic acid 내성 장티푸스균에 대한 항생제 시간-살균 연구", Infection and Chemotherapy, 40(4), pp.207~211 (2008), 대한감염학회
167. Dutta P, "Ceftriaxone therapy in ciprofloxacin treatment failure typhoid fever in children", Indian J Med Res, 113, pp.210~213 (2001)
168. Punjabi NH, "Treatment of severe typhoid fever in children with high dose dexamethasone", Pediatr Infect Dis, 7, pp.598~600 (1988)
169. Hoffman SL, "Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone", N Engl J Med, 310, pp.82~88 (1984)
170. Rogerson SJ, "Hydrocortisone in chloramphenicol-treated severe typhoid fever in Papua New Guinea", Trans R Soc Trop Med Hyg, 85, pp.113~116 (1991)
171. Wain J, "Molecular typing of multiple-antibiotic-resistant Salmonella enterica serovar Typhi from Vietnam: application to acute and relapse cases of typhoid fever", J Clin Microbiol, 37, pp.2466~2472 (1999)
172. Ferreccio C, "Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers", J Infect Dis, 157, pp.1235~1239 (1988)
173. Gotuzzo E, "Use of norfloxacin to treat chronic typhoid carriers", J Infect Dis, 157, pp.1221~1225 (1988)
174. Hosoglu S, "Risk factors for enteric perforation in patients with typhoid Fever", Am J Epidemiol, 160, pp.46~50 (2004)
175. 황종운, "급성 간염으로 발현된 장티푸스 1예", 대한내과학회지, 75(1), pp.77~81 (2008), 대한내과학회
176. Han BH, "A case of typhoid fever complicated with pleurisy and hepatitis", Korean J Med, 65(Suppl 3), pp.S717~S720 (2003)
177. Lee JD, "A case of icteric typhoid hepatitis complicated with splenic infarction", Korean J Gastroenterol, 35, pp.801~805 (2000)
178. 조덕곤, "흉선종의 흉막전이에 동반된 Group D Salmonella 농흉 및 심낭염 -1예 보고-", The Korean Journal of Thoracic and Cardiovascular Surgery, 37(4), pp.382~385 (2004), 대한흉부외과학회
179. 전경만, "뇌수막염, 경추부 척추염 및 경막외 농양으로 발현한 장티푸스 균혈증 1예", Infection and Chemotherapy, 35(1), pp.53~56 (2003), 대한감염학회
180. Rim MS, "Pleural empyema due to Salmonella: a case report", Korean J Intern Med, 15, pp.138~141 (2000)
181. 한상우, "대량의 각혈로 사망한 장티푸스 1예", Infection and Chemotherapy, 36(5), pp.326~329 (2004), 대한감염학회
182. 최정우, "살모넬라 간농양 1예", 대한소화기학회지, 47(4), pp.316~319 (2006), 대한소화기학회
183. Strasberg SM, "Clinical practice. Acute calculous cholecystitis", N Engl J Med, 358, pp.2804~2811 (2008)
184. Miura F, "Flowcharts for the diagnosis and treatment of acute cholangitis and cholecystitis: Tokyo Guidelines", J Hepatobiliary Pancreat Surg, 14, pp.27~34 (2007)
185. Wada K, "Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines", J Hepatobiliary Pancreat Surg, 14, pp.52~58 (2007)
186. Solomkin JS, "Diagnosis and management of complicated intraabdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America", Clin Infect Dis, 50, pp.133~164 (2010)
187. Tanaka A, "Antimicrobial therapy for acute cholangitis: Tokyo Guidelines", J Hepatobiliary Pancreat Surg, 14, pp.59~67 (2007)
188. 김지명, "급성담낭염 환자에서 경피적담낭조루술 시 담즙배양의 유용성과 배양양성 예측인자", The Korean Journal of Laboratory Medicine, 27(4), pp.281~285 (2007), 대한진단검사의학회
189. 고상훈, "담낭염에 대한 임상적 고찰: 비결석성 담낭염과 결석성 담낭염의 비교", 대한외과학회지, 62(3), pp.249~258 (2002), 대한외과학회
190. "Gastrointestinal imaging; right upper quadrant pain"[URL]
191. Ahn BY, "A clinical analysis of acaluclous cholecystitis", J Korean Surg Soc, 53, pp.579~587 (1997)
192. Sung IK, "Bacteriological study of bile in patients with cholangitis due to biliary tract obstruction", Korean J Med, 55, pp.28~32 (1998)
193. Marne C, "Gangrenous cholecystitis and acute cholangitis associated with anaerobic bacteria in bile", Eur J Clin Microbiol, 5, pp.35~39 (1986)
194. Laterre PF, "Antimicrobial therapy for intra-abdominal infections: guidelines from the Infectious Disease Advisory Board (IDAB)", Acta Chir Belg, 106, pp.2~21 (2006)
195. WHO network on antimicrobial resistance monitoring: Korean focal and core laboratory, "Antimicrobial resistance newsletter", ~ (2009)
196. Klevens RM, "Active Bacterial Core surveillance (ABCs) MRSA Invasive methicillinresistant Staphylococcus aureus infections in the United States", JAMA, 298, pp.1763~1771 (2007)
197. Sifri CD, "Infections of the liver and biliary system in Mandell, Douglas, and Bennett's principles and practice of infectious diseases", pp.1035~1044 (2005), Elsevier Churchill Livingston
198. UK Working Party on Acute Pancreatitis, "UK guidelines for the management of acute pancreatitis", Gut, 54, pp.1~9 (2005)
199. Dervenis C, "Diagnosis, objective assessment of severity, and management of acute pancreatitis", Int J Pancreatology, 25, pp.195~210 (1999)
200. American Gastroenterological Association (AGA) Institute on "Management of Acute Pancreatits" Clinical Practice and Economics Committee, "AGA Institute medical position statement on acute pancreatitis", Gastroenterology, 132, pp.2019~2021 (2007)
201. 김태현, "급성 췌장염의 내과적 치료", 대한내과학회지, 75(3), pp.280~284 (2008), 대한내과학회
202. Lee SK, "Medical treatments of necrotizing pancreatitis", Korean J Med, 73, pp.237~242 (2007)
203. Bradley EL 3rd, "A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992", Arch Surg, 128, pp.586~590 (1993)
204. Villatoro E, "Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2006;CD002941", ~ (2006)
205. Sharma VK, "Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis", Pancreas, 22, pp.28~31 (2001)
206. Lumsden A, "Secondary pancreatic infections", Surg Gynecol Obstet, 170, pp.459~467 (1990)
207. Raty S, "Difference in microbes contaminating pancreatic necrosis in biliary and alcoholic pancreatitis", Int J Pancreatol, 24, pp.187~191 (1998)
208. Baron MJ, "Pancreatic infection in Mandell, Douglas, and Bennett's principles and practice of infectious diseases", pp.1045~1053 (2005), Elsevier Churchill Livingston
209. Buchler M, "Human pancreatic tissue concentration of bactericidal antibiotics", Gastroenterology, 103, pp.1902~1908 (1992)
210. Ratschko M, "The role of antibiotic prophylaxis in the treatment of acute pancreatitis", Gastroenterol Clin North Am, 28, pp.641~659 (1999)
211. 하 종, "최근 12년간의 화농성 간농양의 임상양상의 변화", 대한내과학회지, 74(1), pp.37~50 (2008), 대한내과학회
212. Lok KH, "Pyogenic liver abscess: clinical profile, microbiological characteristics, and management in a Hong Kong hospital", J Microbiol Immunol Infect, 41, pp.483~490 (2008)
213. 나병규, "화농성 간농양의 원인균 및 치료의 최근 변화", The Korean Journal of Hepatology, 9(2003), pp.275~283 (2003), 대한간학회
214. "Acute abdominal pain and fever or suspected abdominal abscess"[URL]
215. Lee OJ, "A clinical study on liver abscess", Korean J Gastroentrol, 26, pp.506~520 (1994)
216. Pitt HA, "Factors influencing mortality in the treatment of pyogenic hepatic abscess", Surg Gynecol Obstet, 140, pp.228~234 (1975)
217. Aucott JN, "Amebiasis and "nonpathogenic" intestinal protozoa", Infect Dis Clin North Am, 7, pp.467~485 (1993)
218. Oh YJ, "Clinical study of liver abscess", J Korean Surg Soc, 18, pp.13~22 (1976)
219. Rahimian J, "Pyogenic liver abscess: recent trends in etiology and mortality", Clin Infect Dis, 39, pp.1654~1659 (2004)
220. 위성헌, "최근 10년간 화농성 간농양 141예의 임상적 특성 및 원인균의 항균제 감수성 양상", Infection and Chemotherapy, 40(4), pp.199~206 (2008), 대한감염학회
221. 김대원, "최근 10년간 간농양의 임상적 고찰", 대한내과학회지, 66(5), pp.478~486 (2004), 대한내과학회
222. 서태진, "최근 15년간 광주？전남지역에서 발생한 간농양의 임상적 고찰", 대한내과학회지, 68(1), pp.26~38 (2005), 대한내과학회
223. Jin HY, "Comparison of pyogenic liver abscesses caused by Klebsiella pneumoniae and non-K. pneumoniae pathogens", Korean J Infect Dis, 33, pp.202~205 (2001)
224. Cheng HP, "Extended-spectrum cephalosporin compared to cefazolin for treatment of Klebsiella pneumoniae -caused liver abscess", Antimicrob Agents Chemother, 47, pp.2088~2092 (2003)
225. Lee SS, "Predictors of septic metastatic infection and mortality among patients with Klebsiella pneumoniae liver abscess", Clin Infect Dis, 47, pp.642~650 (2008)
226. Yoo HM, "The changing patterns of liver abscess during the past 20 years: a study of 482 cases", Yonsei Med J, 34, pp.340~351 (1993)
227. Kim SB, "A clinical study on liver abscess", J Korean Surg Soc, 43, pp.691~698 (1992)
228. Neuschwander-Tetri BA, "Bacterial, parasitic, fungal, and granulomatous liver diseases in Cecil Medicine", pp.1128~1135 (2007), Saunders
229. Haque R, "Amebiasis", N Engl J Med, 348, pp.1565~1573 (2003)
230. Stanley SL Jr, "Amoebiasis", Lancet, 361, pp.1025~1034 (2003)
231. Aucott JN, "Amebiasis and "nonpathogenic" intestinal protozoa", Infect Dis Clin North Am, 7, pp.467~485 (1993)
232. Miller RA, "Amebiasis, giardiasis, and other intestinal protozoal infections in The travel & tropical medicine manual", pp.325~341 (1995), WB Saunders
233. Tan YM, "An appraisal of surgical and percutaneous drainage for pyogenic liver abscesses larger than 5 cm", Ann Surg, 241, pp.485~490 (2005)
234. Hope WW, "Optimal treatment of hepatic abscess", Am Surg, 74, pp.178~182 (2008)
235. Zerem E, "Sonographically guided percutaneous cahtheter drainage versus needle aspiration in the management of pyogenic liver abscess", AJR Am J Roentgenol, 189, pp.W138~W142 (2007)
236. Giorgio A, "Percutaneous needle aspiration of multiple pyogenic abscesses of the liver: 13-year single-center experience", AJR Am J Roentgenol, 187, pp.1585~1590 (2006)
237. Barakate MS, "Pyogenic liver abscess: a review of 10 years' experience in management", Aust N Z J Surg, 69, pp.205~209 (1999)
238. Ch Yu S, "Pyogenic liver abscess: treatment with needle aspiration", Clin Radiol, 52, pp.912~916 (1997)
239. Giorgio A, "Pyogenic liver abscesses: 13 years of experience in percutaneous needle aspiration with US guidance", Radiology, 195, pp.122~124 (1995)
240. Chavez-Tapia NC, "Image-guided percutaneous procedure plus metronidazole versus metronidazole alone for uncomplicated amoebic liver abscess. Cochrane Database Syst Rev 2009; CD004886", ~ (2009)
241. Sharma MP, "Needle aspiration of amoebic liver abscess", BMJ, 299, pp.1308~1309 (1989)
242. Van Allan RJ, "Uncomplicated amebic liver abscess: prospective evaluation of percutaneous therapeutic aspiration", Radiology, 183, pp.827~830 (1992)
243. Weinke T, "Amebic liver abscess-rare need for percutaneous treatment modalities", Eur J Med Res, 7, pp.25~29 (2002)
244. Blessmann J, "Treatment of amoebic liver abscess with metronidazole alone or in combination with ultrasound-guided needle aspiration: a comparative, prospective and randomized study", Trop Med Int Health, 8, pp.1030~1034 (2003)
245. Mazuski JE, "Antimicrobial treatment for intra-abdominal infections", Expert Opin Pharmacother, 8, pp.2933~2945 (2007)
246. Mazuski JE, "Intraabdominal infections", Surg Clin North Am, 89, pp.421~437 (2009)
247. Lee SB, "Clinical characteristics and prognostic factors of bacteremia and sepsis", Korean J Med, 56, pp.347~358 (1999)
248. 홍석경, "3차 대학병원 내과계 중환자실 내 중증 패혈증의 유병률과 예후인자", 대한중환자의학회지, 24(1), pp.28~32 (2009), 대한중환자의학회
249. Infectious Diseases Society of Taiwan, "Guidelines for antimicrobial therapy of intraabdominal infections in adults", J Microbiol Immunol Infect, 41, pp.279~281 (2008)
250. 박상원, "국내 지역사회 3차 병원에서 최근 2년간 경험한 지역사회 균혈증의 원인과 예후에 관한 분석", Infection and Chemotherapy, 37(5), pp.255~264 (2005), 대한감염학회
251. Yun SJ, "Culture-sensitivity test and infectious complication in perforated appendicitis", J Korean Soc Coloproctol, 16, pp.73~77 (2000)
252. Roehrborn A, "The microbiology of postoperative peritonitis", Clin Infect Dis, 33, pp.1513~1519 (2001)
253. Swenson BR, "Choosing antibiotics for intra-abdominal infections: what do we mean by “high risk”?", Surg Infect (Larchmt), 10, pp.29~39 (2009)
254. Kang CI, "Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum betalactamase-producing Escherichia coli", Eur J Clin Microbiol Infect Dis, 27, pp.85~88 (2008)
255. Goldstein EJ, "In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections", Antimicrob Agents Chemother, 50, pp.148~155 (2006)
256. Solomkin JS, "Results of a randomized trial comparing sequential intravenous", oral treatment with ciprofloxacin plus metronidazole to imipenem, Ann Surg, pp.1996, 223[DOI]
257. Solomkin JS, "Results of a clinical trial of clinafloxacin versus imipenem", cilastin for intraabdominal infections, 2001, pp.233, 79~87
258. Wagner JM, "Does this patient have appendicitis?", JAMA, 276, pp.1589~1594 (1996)
259. Silen W, "Cope’s early diagnosis of the acute abdomen", pp.298~ (2005), Oxford University Press
260. Pinto Leite N, "CT evaluation of appendicitis and its complications: imaging techniques and key diagnostic findings", AJR Am J Roentgenol, 185, pp.406~417 (2005)
261. Urban BA, "Targeted helical CT of the acute abdomen: appendicitis, diverticulitis, and small bowel obstruction", Semin Ultrasound CT MR, 21, pp.20~39 (2000)
262. Doria AS, "US or CT for diagnosis of appendicitis in children and adults? A meta-analysis", Radiology, 241, pp.83~94 (2006)
263. Oh BY, "Early diagnosis of acute appendicitis by use of ultrasonography in emergency department", J Korean Soc Emerg Med, 9, pp.586~594 (1998)
264. Cueto J, "Morbidity of laparoscopic surgery for complicated appendicitis: an international study", Surg Endosc, 20, pp.717~720 (2006)
265. Akinci D, "Percutaneous drainage of 300 intraperitoneal abscesses with long-term follow-up", Cardiovasc Intervent Radiol, 28, pp.744~750 (2005)
266. De Waele JJ, "Blood stream infections of abdominal origin in the intensive care unit: characteristics and determinants of death", Surg Infect (Larchmt), 9, pp.171~177 (2008)
267. Dougherty SH, "Antimicrobial culture and susceptibility testing has little value for routine management of secondary bacterial peritonitis", Clin Infect Dis, 25(Suppl 2), pp.S258~S261 (1997)
268. Kokoska ER, "The impact of intraoperative culture on treatment and outcome in children with perforated appendicitis", J Pediatr Surg, 34, pp.749~753 (1999)
269. Montravers P, "Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy", Clin Infect Dis, 23, pp.486~494 (1996)
270. Marshall JC, "Source control in the management of severe sepsis and septic shock: an evidence-based review", Crit Care Med, 32(Suppl 11), pp.S513~S526 (2004)
271. Koperna T, "Prognosis and treatment of peritonitis. Do we need new scoring systems?", Arch Surg, 131, pp.180~186 (1996)
272. Koperna T, "Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection", World J Surg, 24, pp.32~37 (2000)
273. Mulier S, "Factors affecting mortality in generalized post operative peritonitis: multivariate analysis in 96 patients", World J Surg, 27, pp.379~384 (2003)
274. Grunau G, "Predictors of outcome in patients with postoperative intra-abdominal infection", Eur J Surg, 162, pp.619~625 (1996)
275. Betsch A, "CT-guided percutaneous drainage of intra-abdominal abscesses: APACHE III score stratification of 1-year results. Acute physiology, age, chronic health evaluation", Eur Radiol, 12, pp.2883~2889 (2002)
276. Theisen J, "Current concepts of percutaneous abscess drainage in postoperative retention", J Gastrointest Surg, 9, pp.280~283 (2005)
277. Maher MM, "The inaccessible or undrainable abscess: how to drain it", Radiographics, 24, pp.717~735 (2004)
278. Allo MD, "Ticarcillin", clavulanate versus imipenem, Am Surg, pp.1999, 65[DOI]
279. OOliva ME, "A multicenter trial of the efficacy and safety of tigecycline versus imipenem", cilastatin in patients with complicated intraabdominal infections, 2005, pp.5, 88~
280. Namias N, "Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin", tazobactam in treatment of complicated intraabdominal infections in hospitalized adults, 2007, pp.8, 15~28
281. Malangoni MA, "Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections", Ann Surg, 244, pp.204~211 (2006)
282. Paterson DL, "In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)", J Antimicrob Chemother, 55, pp.965~973 (2005)
283. 이경원, "Increasing Prevalence of Vancomycin-Resistant Enterococci, and Cefoxitin-, Imipenem- and Fluoroquinolone-Resistant Gram-Negative Bacilli: a KONSAR Study in 2002", Yonsei Medical Journal, 45(4), pp.598~608 (2004), 연세대학교의과대학
284. Snydman DR, "Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis", Antimicrob Agents Chemother, 36, pp.540~544 (1992)
285. Aldridge KE, "In vitro susceptibilities of the Bacteroides fragilis group species: change in isolation rates significantly affects overall susceptibility data", J Clin Microbiol, 40, pp.4349~4352 (2002)
286. Snydman DR, "Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996", Antimicrob Agents Chemother, 43, pp.2417~2422 (1999)
287. Snydman DR, "National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997?2000", Clin Infect Dis, 35(Suppl 1), pp.S126~S134 (2002)
288. 노경호, "Resistance Trends of Bacteroides fragilis Group Over an 8-Year Period, 1997-2004, in Korea", The Korean Journal of Laboratory Medicine, 29(4), pp.293~298 (2009), 대한진단검사의학회
289. Oh H, "Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone", Infection, 28, pp.272~277 (2000)
290. Sullivan A, "Effect of antimicrobial agents on the ecological balance of human microflora", Lancet Infect Dis, 1, pp.101~114 (2001)
291. 조용균, "성인의 복잡성 복강내 감염증의 치료에서 Ertapenem 단독투여와 Ceftriaxone과Metronidazole 병용투여의 안전성과 유효성 평가를위한 다기관, 공개, 무작위, 비교 임상연구", Infection and Chemotherapy, 37(6), pp.330~336 (2005), 대한감염학회
292. Yellin AE, "The role of Pseudomonas species in patients treated with ampicillin and Sulbactam for gangrenous and perforated appendicitis", Surg Gynecol Obstet, 161, pp.303~307 (1985)
293. Cohn SM, "Comparison of intravenous", oral ciprofloxacin plus metronidazole versus piperacillin, Ann Surg, pp.2000, 232[DOI]
294. Ohlin B, "Piperacillin", tazobactam compared with cefuroxime, Eur J Surg, pp.1999, 165[DOI]
295. Mosdell DM, "Antibiotic treatment for surgical peritonitis", Ann Surg, 214, pp.543~549 (1991)
296. Wacha H, "Risk factors associated with intraabdominal infections: a prospective multicenter study", Langenbecks Arch Surg, 384, pp.24~32 (1999)
297. Montravers P, "Candida as a risk factor for mortality in peritonitis", Crit Care Med, 34, pp.646~652 (2006)
298. Montravers P, "Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study", J Antimicrob Chemother, 63, pp.785~794 (2009)
299. Montravers P, "Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections", Ann Surg, 239, pp.409~416 (2004)
300. Ibrahim EH, "The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting", Chest, 118, pp.146~155 (2000)
301. Lodise TP Jr, "Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection", Antimicrob Agents Chemother, 51, pp.3510~3515 (2007)
302. Pappas PG, "Guidelines for treatment of candidiasis", Clin Infect Dis, 38, pp.161~189 (2004), Infectious Diseases Society of America
303. Calandra T, "Clinical significance of Candida isolated from peritoneum in surgical patients", Lancet, 2, pp.1437~1440 (1989)
304. Solomkin JS, "The role of Candida in intraperitoneal infections", Surgery, 88, pp.524~530 (1980)
305. Fierobe L, "Methicillin-resistant Staphylococcus aureus as a causative agent of postoperative intra-abdominal infection: relation to nasal colonization", Clin Infect Dis, 29, pp.1231~1238 (1999)
306. Patel M, "USA300 genotype community-associated methicillinresistant Staphylococcus aureus as a cause of surgical site infections", J Clin Microbiol, 45, pp.3431~3433 (2007)
307. Trividic M, "Methi-resistant Staphylococcus aureus in dermatological practice: origin, risk factors and outcome", Ann Dermatol Venereol, 129, pp.27~29 (2002)
308. Rojo D, "Analysis of risk factors associated with nosocomial bacteraemias", J Hosp Infect, 42, pp.135~141 (1999)
309. Jensen AG, "Risk factors for hospital-acquired Staphylococcus aureus bacteremia", Arch Intern Med, 159, pp.1437~1444 (1999)
310. Kim OS, "Rate of nasal colonization of methicillin-resistant Staphylococcus aureus at admission to a medical intensive care unit", Korean Journal of Nosocomial Infection Control, 12, pp.42~49 (2007)
311. Blot S, "Critical issues in the clinical management of complicated intra-abdominal infections", Drugs, 65, pp.1611~1620 (2005)
312. Burnett RJ, "Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial", Surgery, 118, pp.716~721 (1995)
313. Sitges-Serra A, "Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis", Br J Surg, 89, pp.361~367 (2002)
314. Falagas ME, "Risk factors leading to clinical failure in the treatment of intraabdominal or skin", soft tissue infections, 1996, pp.15, 913~921
315. Krobot K, "Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery", Eur J Clin Microbiol Infect Dis, 23, pp.682~687 (2004)
316. Sturkenboom MC, "Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs", Br J Clin Pharmacol, 60, pp.438~443 (2005)
317. Bartlett JG, "Clinical recognition and diagnosis of Clostridium difficile infection", Clin Infect Dis, 46(Suppl 1), pp.S12~S18 (2008)
318. Wilton P, "Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness", J Health Serv Res Policy, 7, pp.111~117 (2002)
319. Mazuski JE, "The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations", Surg Infect (Larchmt), 3, pp.175~233 (2002), Therapeutic Agents Committee of the Surgical Infections Society
320. Mazuski JE, "The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal in fections: an executive summary", Surg Infect (Larchmt), 3, pp.161~173 (2002), Therapeutic Agents Committee of the Surgical Infections Society
321. Gleisner AL, "Infective complications according to duration of antibiotic treatment in acute abdomen", Int J Infect Dis, 8, pp.155~162 (2004)
322. Blot S, "Critical issues in the clinical management of complicated intra-abdominal infections", Drugs, 65, pp.1611~1620 (2005)
323. Hedrick TL, "Can we define the ideal duration of antibiotic therapy?", Surg Infect (Larchmt), 7, pp.419~432 (2006)
324. Lennard ES, "Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis", Ann Surg, 195, pp.19~24 (1982)

관련 논문AI추천